NCT05179213

Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma

Azacytidine Combined With Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma: a Multicenter Single Arm Phase II Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with chidamide in the treatment of relapsed/refractory angioimmunoblastic T-cell lymphoma.

Detailed description

Azacytidine was given subcutaneously at a dose of 75 mg/m2 on days 1-7. Chidamide was an oral tablet which was administered 20mg twice weekly. This regimen was repeated every 28 days. Treatment was given until disease progression, unacceptable toxicity, or patient/investigator discretion.

Conditions

• Angioimmunoblastic T-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Azacitidine	75 mg/m2 subcutaneously on days 1-7
DRUG	Chidamide	20mg orally per week continuously

Timeline

• Start date: 2022-01-01
• Primary completion: 2024-01-01
• Completion: 2024-05-01
• First posted: 2022-01-05
• Last updated: 2022-01-05

Locations

1 site across 1 country: China